Pub Date : 2016-09-30DOI: 10.4172/2167-0943.1000213
Manopriya T, Khalid G, Alshaari Aa, Sheriff Ds
NAFLD is an emerging problem in Asia, with raising prevalence and strong impact on the health care system. More and more people will suffer from not only the liver impairment of NAFLD but also the associated metabolic diseases e.g. DM and hypertension. The incidence of DM, hypertension, coronary heart diseases (CHD) and stroke will increase together with the prevalence of NAFLD and the health service expenditure will rise in coming decades. However the prevalence of and the metabolic diseases associated with NAFLD are not well studied in Asian populations. The objective of this project is to systematically review the articles related to NAFLD.
{"title":"Non-alcoholic Fatty Liver Disease (NAFLD) - An Emerging Public HealthProblem","authors":"Manopriya T, Khalid G, Alshaari Aa, Sheriff Ds","doi":"10.4172/2167-0943.1000213","DOIUrl":"https://doi.org/10.4172/2167-0943.1000213","url":null,"abstract":"NAFLD is an emerging problem in Asia, with raising prevalence and strong impact on the health care system. More and more people will suffer from not only the liver impairment of NAFLD but also the associated metabolic diseases e.g. DM and hypertension. The incidence of DM, hypertension, coronary heart diseases (CHD) and stroke will increase together with the prevalence of NAFLD and the health service expenditure will rise in coming decades. However the prevalence of and the metabolic diseases associated with NAFLD are not well studied in Asian populations. The objective of this project is to systematically review the articles related to NAFLD.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78095859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-30DOI: 10.4172/2167-0943.1000210
Keerthi Kupsal, S. Mudigonda, Sai Nvbk, Krishnaveni Neelala, S. Hanumanth
Type 2 Diabetes mellitus (T2D) is a worldwide chronic epidemic with increasing incidence. The current algorithm for medical management of type 2 diabetes includes the pharmacological treatment with nine classes of anti-diabetic drugs. Among the nine classes of drugs approved, metformin, an oral hypoglycemic agent from the biguanide family is widely prescribed as the first-line anti-diabetic monotherapy for the treatment of initially diagnosed T2D individuals. The failure of monotherapy to achieve sustain glycemic control prompted the early use of aggressive combination therapies with other anti-diabetic drugs. The primary aim of T2D treatment is to achieve target glycemic control and reducing further complications of diabetes. Hence, fixed dose combination drugs are preferable in order to reduce pill burden and capital investment. Single pill combinations containing drugs for two different diseases can also be prescribed for avoiding extra medication and to reduce further diabetic complications. Our review addresses the mode of action of anti-diabetic drugs and their combinatorial therapy with metformin.
{"title":"Metformin Combinatorial Therapy for Type 2 Diabetes Mellitus","authors":"Keerthi Kupsal, S. Mudigonda, Sai Nvbk, Krishnaveni Neelala, S. Hanumanth","doi":"10.4172/2167-0943.1000210","DOIUrl":"https://doi.org/10.4172/2167-0943.1000210","url":null,"abstract":"Type 2 Diabetes mellitus (T2D) is a worldwide chronic epidemic with increasing incidence. The current algorithm for medical management of type 2 diabetes includes the pharmacological treatment with nine classes of anti-diabetic drugs. Among the nine classes of drugs approved, metformin, an oral hypoglycemic agent from the biguanide family is widely prescribed as the first-line anti-diabetic monotherapy for the treatment of initially diagnosed T2D individuals. The failure of monotherapy to achieve sustain glycemic control prompted the early use of aggressive combination therapies with other anti-diabetic drugs. The primary aim of T2D treatment is to achieve target glycemic control and reducing further complications of diabetes. Hence, fixed dose combination drugs are preferable in order to reduce pill burden and capital investment. Single pill combinations containing drugs for two different diseases can also be prescribed for avoiding extra medication and to reduce further diabetic complications. Our review addresses the mode of action of anti-diabetic drugs and their combinatorial therapy with metformin.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84245338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-30DOI: 10.4172/2167-0943.1000209
Arun Raghavan, Nanditha Arun, S. Chamukuttan, Priscilla Susairaj, V. Lakshminarayanan, Ramachandran Ambady
Background: To compare cardio metabolic characteristics of Asian Indians with incident type 2 diabetes diagnosed by Oral Glucose Tolerance Test (OGTT) or by Glycosylated Haemoglobin (HbA1c). Research Design and Methods: Data from two Indian Diabetes Prevention Studies in persons with Impaired Glucose Tolerance (IGT) was used. In 314 persons, diabetes was diagnosed by OGTT and another 67 persons had only HbA1c values ≥ 6.5% (≥48 mmol/mol). Cardiometabolic characteristics were compared in 3 sub-groups-1: Persons with positive OGTT only (HbA1c<6.5% (<48 mmol/mol) (n=125), 2: Persons with positive HbA1c but negative OGTT (n=67), 3: Those with both HbA1c and OGTT positive (n=189). Results: Diagnostic sensitivity of HbA1c was 67.2% when compared with OGTT criteria. Prevalence of obesity, abdominal obesity, hypertension, insulin resistance and lipid abnormalities were similar in all groups. Persons in groups-1 and 2 had similar metabolic characteristics, but for higher plasma glucose in the former group and higher HbA1c in the latter group. Prevalence of abnormalities was similar in both groups. Group with both the tests positive, had higher levels of insulin resistance. Conclusion: Metabolic characteristics of incident diabetic cases identified either by OGTT or by HbA1c were similar, except for a higher prevalence of insulin resistance among those who had both tests positive.
{"title":"Metabolic Profile of Persons with Newly Diagnosed Diabetes Using eitherGlycoslated Haemoglobin or Oral Glucose Tolerance Test in Primary PreventionTrials in Asian Indians","authors":"Arun Raghavan, Nanditha Arun, S. Chamukuttan, Priscilla Susairaj, V. Lakshminarayanan, Ramachandran Ambady","doi":"10.4172/2167-0943.1000209","DOIUrl":"https://doi.org/10.4172/2167-0943.1000209","url":null,"abstract":"Background: To compare cardio metabolic characteristics of Asian Indians with incident type 2 diabetes diagnosed by Oral Glucose Tolerance Test (OGTT) or by Glycosylated Haemoglobin (HbA1c). Research Design and Methods: Data from two Indian Diabetes Prevention Studies in persons with Impaired Glucose Tolerance (IGT) was used. In 314 persons, diabetes was diagnosed by OGTT and another 67 persons had only HbA1c values ≥ 6.5% (≥48 mmol/mol). Cardiometabolic characteristics were compared in 3 sub-groups-1: Persons with positive OGTT only (HbA1c<6.5% (<48 mmol/mol) (n=125), 2: Persons with positive HbA1c but negative OGTT (n=67), 3: Those with both HbA1c and OGTT positive (n=189). Results: Diagnostic sensitivity of HbA1c was 67.2% when compared with OGTT criteria. Prevalence of obesity, abdominal obesity, hypertension, insulin resistance and lipid abnormalities were similar in all groups. Persons in groups-1 and 2 had similar metabolic characteristics, but for higher plasma glucose in the former group and higher HbA1c in the latter group. Prevalence of abnormalities was similar in both groups. Group with both the tests positive, had higher levels of insulin resistance. Conclusion: Metabolic characteristics of incident diabetic cases identified either by OGTT or by HbA1c were similar, except for a higher prevalence of insulin resistance among those who had both tests positive.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"111 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79280948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-11DOI: 10.4172/2167-0943.1000212
B. Kornah, H. Safwat, Tharwat Abdel ghany, Mohamed Abdel-AAl
Aim: Pathologic fractures occur as a result of weakening of the mechanical properties of bone. There are many conditions, which lead to bone softening. There are neoplastic and non-neoplastic diseases that cause pathologic fractures. The aim is to evaluate and to highlight on value of prophylactic fixation of impending fractures in abnormal bone situation to prevent occurrence of pathological fracture and its complications. Patients and methods: Between 2003 and 2009, study on forty-nine patient (35 females and 14 males) between the age of 20 and 65 years with an average age of 49.9 years with expected possibility of fractures of lower extremities. The entire patient with fractures risks prophylactic fixation has done. Different types of fixation either surface plating (dynamic hip screws), medullary (Gamma nails or locking nail) or external fixation in cases unsuitable for surgery was used according to the type and the site of the deformity in combination of management of primary condition. Results: Most patients had significant relief of pain. 35 (71.5%) of patients with impending fracture were ambulatory after therapy and able to walk outdoor while 10 (20.5%) of patients could walk inside door. Three patients (6%) using wheel chair, and they were on renal dialysis. Only one patient (2%) was not able to walk, and he was not cooperative for unknown reason. The mean duration of hospitalization was 21 days (range from 7 to 35 days). That time included preoperative period of investigation and preparation and post-operative surgery and rehabilitation. Discussion: Pathological fractures create a serious morbidity in patients with bone disease. Orthopedic surgeons who look after patients with skeletal lesions should focus on proactive treatments designed to prevent pathologic fractures before they occur. Prophylactic fixations have decreased morbidity compared with patient's sustained fractures before fixation. Conclusion: Surgical fixation of fractures in weight-bearing long bones with impending fractures provides pain relief, and a functionally stable and durable construct. It helps early an ambulation and prevents fracture's complication. It allows independent function and avoids irretrievable catastrophes.
{"title":"Prophylactic Fixation of Impending Fractures","authors":"B. Kornah, H. Safwat, Tharwat Abdel ghany, Mohamed Abdel-AAl","doi":"10.4172/2167-0943.1000212","DOIUrl":"https://doi.org/10.4172/2167-0943.1000212","url":null,"abstract":"Aim: Pathologic fractures occur as a result of weakening of the mechanical properties of bone. There are many conditions, which lead to bone softening. There are neoplastic and non-neoplastic diseases that cause pathologic fractures. The aim is to evaluate and to highlight on value of prophylactic fixation of impending fractures in abnormal bone situation to prevent occurrence of pathological fracture and its complications. Patients and methods: Between 2003 and 2009, study on forty-nine patient (35 females and 14 males) between the age of 20 and 65 years with an average age of 49.9 years with expected possibility of fractures of lower extremities. The entire patient with fractures risks prophylactic fixation has done. Different types of fixation either surface plating (dynamic hip screws), medullary (Gamma nails or locking nail) or external fixation in cases unsuitable for surgery was used according to the type and the site of the deformity in combination of management of primary condition. Results: Most patients had significant relief of pain. 35 (71.5%) of patients with impending fracture were ambulatory after therapy and able to walk outdoor while 10 (20.5%) of patients could walk inside door. Three patients (6%) using wheel chair, and they were on renal dialysis. Only one patient (2%) was not able to walk, and he was not cooperative for unknown reason. The mean duration of hospitalization was 21 days (range from 7 to 35 days). That time included preoperative period of investigation and preparation and post-operative surgery and rehabilitation. Discussion: Pathological fractures create a serious morbidity in patients with bone disease. Orthopedic surgeons who look after patients with skeletal lesions should focus on proactive treatments designed to prevent pathologic fractures before they occur. Prophylactic fixations have decreased morbidity compared with patient's sustained fractures before fixation. Conclusion: Surgical fixation of fractures in weight-bearing long bones with impending fractures provides pain relief, and a functionally stable and durable construct. It helps early an ambulation and prevents fracture's complication. It allows independent function and avoids irretrievable catastrophes.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"52 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80031991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-07-24DOI: 10.4172/2167-0943.1000206
D. Luis, R. Aller, O. Izaola
Background: The SNP of the leptin receptor (Lys656Asn) has been related with metabolic parameters. The aim of our design was to evaluate the influence of Lys656Asn variant of Leptin receptor gene on weight loss and metabolic parameters secondary to a high protein/low carbohydrate vs. a standard hypocaloric diets. Design: A total of 280 obese subjects were randomly allocated to one of two diets during 9 months (Diet HP (high protein-low carbohydrate hypocaloric diet) and Diet S (standard protein hypocaloric diet)). Results: After both diets and in both genotypes, body mass index (BMI), fat mass, weight, systolic blood pressure and waist circumference decreased, without differences between both diets. With the diet type HP and in both genotypes, triglycerides decreased. In subjects with Lys656Lys genotype, glucose, insulin levels, HOMA-R, total cholesterol and LDL- total cholesterol decreased after HP diet. No statistical changes were detected in Asn allele carriers. After diet S and in patients with Lys656Lys genotypes, only total cholesterol, triglycerides and LDL- total cholesterol decreased, without changes in Asn allele carriers. Conclusion: Obese subjects with Asn656 allele have a different metabolic response than Lys656Lys genotype subjects, secondary to the same weight loss with two different hypocaloric diets.
{"title":"Effects of a High Protein/Low Carbohydrate Versus a Standard Hypocaloric Diet on Weight and Cardiovascular Risk Factors, Role of a Lys656asn Polymorphism of Leptin Receptor Gene","authors":"D. Luis, R. Aller, O. Izaola","doi":"10.4172/2167-0943.1000206","DOIUrl":"https://doi.org/10.4172/2167-0943.1000206","url":null,"abstract":"Background: The SNP of the leptin receptor (Lys656Asn) has been related with metabolic parameters. The aim of our design was to evaluate the influence of Lys656Asn variant of Leptin receptor gene on weight loss and metabolic parameters secondary to a high protein/low carbohydrate vs. a standard hypocaloric diets. \u0000Design: A total of 280 obese subjects were randomly allocated to one of two diets during 9 months (Diet HP (high protein-low carbohydrate hypocaloric diet) and Diet S (standard protein hypocaloric diet)). \u0000Results: After both diets and in both genotypes, body mass index (BMI), fat mass, weight, systolic blood pressure and waist circumference decreased, without differences between both diets. With the diet type HP and in both genotypes, triglycerides decreased. In subjects with Lys656Lys genotype, glucose, insulin levels, HOMA-R, total cholesterol and LDL- total cholesterol decreased after HP diet. No statistical changes were detected in Asn allele carriers. After diet S and in patients with Lys656Lys genotypes, only total cholesterol, triglycerides and LDL- total cholesterol decreased, without changes in Asn allele carriers. Conclusion: Obese subjects with Asn656 allele have a different metabolic response than Lys656Lys genotype subjects, secondary to the same weight loss with two different hypocaloric diets.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78794431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-07-12DOI: 10.4172/2167-0943.1000207
C. Tosti, V. Cappelli, V. Leo
Background: Insulin resistance is characteristic of patients with metabolic syndrome and it’s more pronounced in overweight patients. In the long term there may be cardiovascular and pressor consequences. Lifestyle and diet changes may partly improve these aspects. The use of insulin-sensitizing drugs such as metformin gives good results, although side effects limit its use. Recently, new molecules exerting a similar effect without side effects have been put on the market, such as the d-chiro-inositol, a new insulin-sensitizing molecule. Have been proposed various associations between inositol and ingredients able to potentiate its therapeutic effect. Materials and methods: This was a prospective study. 40 women were recruited aged >40 years in perimenopause with metabolic syndrome with insulin resistance, altered lipid parameters and with a BMI>25. Were evaluated: BMI, insulin levels and fasting plasma glucose, lipid profile (total cholesterol, HDL, triglycerides). The patients were divided into 2 groups: group A treated with a new oral product containing d-chiro-inositol 100 mg, monacolin-K 3 mg, bergamot extract 250 mg, methylfolate 200 mcg and natural vitamin K2 45 mcg (Mesix®) in tablets for 6 months, one tablet per day. Group B not treated and followed for 6 months. Results:The results demonstrated a significant reduction in the levels of almost all parameters in the group treated with this new supplement, without any side effect. Conclusions:This innovative natural supplement, thanks to the synergy of action of its components, can be a new effective alternative in prevention and treatment of metabolic syndrome in perimenopausal women.
背景:胰岛素抵抗是代谢综合征患者的特征，在超重患者中更为明显。从长期来看，可能会对心血管和血压造成影响。生活方式和饮食的改变可能在一定程度上改善这些方面。使用胰岛素增敏药物如二甲双胍取得了良好的效果，尽管其副作用限制了其使用。最近，市场上出现了具有类似效果且无副作用的新分子，如新型胰岛素增敏分子d-氨基肌醇。已经提出了肌醇与能够增强其治疗效果的成分之间的各种关联。材料与方法:本研究为前瞻性研究。招募了40名年龄>40岁的围绝经期代谢综合征伴胰岛素抵抗、脂质参数改变、BMI>25的女性。评估:BMI、胰岛素水平、空腹血糖、血脂(总胆固醇、高密度脂蛋白、甘油三酯)。将患者分为两组:A组患者口服含d-手性肌醇100 mg、莫那可林- k 3 mg、佛手柑提取物250 mg、甲基叶酸200 mcg、天然维生素K2 45 mcg (Mesix®)片剂，疗程6个月，每天1片。B组不治疗，随访6个月。结果:结果表明，在接受这种新补充剂治疗的组中，几乎所有参数的水平都显着降低，没有任何副作用。结论:这种创新的天然补品，由于其成分的协同作用，可以成为预防和治疗围绝经期妇女代谢综合征的一种新的有效选择。
{"title":"A New Oral Formulation based on D-Chiro-Inositol/Monacolin K/BergamotExtract/Methylfolate and Vitamin K2 in Prevention and Treatment of MetabolicSyndrome in Perimenopausal Women with a BMI>25 Kg/m2","authors":"C. Tosti, V. Cappelli, V. Leo","doi":"10.4172/2167-0943.1000207","DOIUrl":"https://doi.org/10.4172/2167-0943.1000207","url":null,"abstract":"Background: Insulin resistance is characteristic of patients with metabolic syndrome and it’s more pronounced in overweight patients. In the long term there may be cardiovascular and pressor consequences. Lifestyle and diet changes may partly improve these aspects. The use of insulin-sensitizing drugs such as metformin gives good results, although side effects limit its use. Recently, new molecules exerting a similar effect without side effects have been put on the market, such as the d-chiro-inositol, a new insulin-sensitizing molecule. Have been proposed various associations between inositol and ingredients able to potentiate its therapeutic effect. \u0000Materials and methods: This was a prospective study. 40 women were recruited aged >40 years in perimenopause with metabolic syndrome with insulin resistance, altered lipid parameters and with a BMI>25. Were evaluated: BMI, insulin levels and fasting plasma glucose, lipid profile (total cholesterol, HDL, triglycerides). The patients were divided into 2 groups: group A treated with a new oral product containing d-chiro-inositol 100 mg, monacolin-K 3 mg, bergamot extract 250 mg, methylfolate 200 mcg and natural vitamin K2 45 mcg (Mesix®) in tablets for 6 months, one tablet per day. Group B not treated and followed for 6 months. \u0000Results:The results demonstrated a significant reduction in the levels of almost all parameters in the group treated with this new supplement, without any side effect. \u0000Conclusions:This innovative natural supplement, thanks to the synergy of action of its components, can be a new effective alternative in prevention and treatment of metabolic syndrome in perimenopausal women.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77465464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-27DOI: 10.4172/2167-0943.1000E118
Hong Wang
Metabolic syndrome is characterized by systemic insulin resistance that impairs the ability of insulin to regulate fuel (such as glucose and fat) metabolism. This syndrome has become a global epidemic problem with estimates of prevalence ranging from 20 to 40% in different populations and has been recognized as a powerful risk factor for the development of cardiovascular disease and type 2 diabetes. Thus, effectively fighting this disastrous health problem is a matter of utmost urgency. To fulfill this mission, our journal, Journal of Metabolic Syndrome, started its long journey in early 2012. Since then, we have set up the scope to publish the most exciting original research articles and reviews on metabolic syndrome with the purpose to facilitate the research and teaching and to provide reference for this field. So far, we have made a great progress and have successfully published 5 volumes with 18 regular issues plus additional special issues. The valuable information from these published articles has become the important resource for researchers and clinicians to fight and eventually to conquer this syndrome.
{"title":"Break the Resistance to Fuel Metabolism: A Long Journey with Bright Future","authors":"Hong Wang","doi":"10.4172/2167-0943.1000E118","DOIUrl":"https://doi.org/10.4172/2167-0943.1000E118","url":null,"abstract":"Metabolic syndrome is characterized by systemic insulin resistance that impairs the ability of insulin to regulate fuel (such as glucose and fat) metabolism. This syndrome has become a global epidemic problem with estimates of prevalence ranging from 20 to 40% in different populations and has been recognized as a powerful risk factor for the development of cardiovascular disease and type 2 diabetes. Thus, effectively fighting this disastrous health problem is a matter of utmost urgency. To fulfill this mission, our journal, Journal of Metabolic Syndrome, started its long journey in early 2012. Since then, we have set up the scope to publish the most exciting original research articles and reviews on metabolic syndrome with the purpose to facilitate the research and teaching and to provide reference for this field. So far, we have made a great progress and have successfully published 5 volumes with 18 regular issues plus additional special issues. The valuable information from these published articles has become the important resource for researchers and clinicians to fight and eventually to conquer this syndrome.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82171093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-20DOI: 10.4172/2167-0943.1000205
I. Dedinská, M. StanÄík, L. Laca, J. Miklušica, D. Kantárová, J. Ulinako, J. Janek, P. Galajda, M. MokáÅ
Purpose: New-onset diabetes mellitus after transplantation (NODAT) is a well-known complication of transplantation. Materials and methods: Retrospectively, we detected CMV replication (PCR) in every month after transplantation of kidney in the first 12 months after transplantation in patients in a homogenous group from the aspect of immunosuppresion. Results: In the group of 167 patients (control group: n = 103, NODAT group: n = 64), the average value of CMV viremia was without any significant difference between the NODAT group and the control group (P = 0.9285). In the 10th month after kidney transplantation, we recorded significantly higher CMV viremia in the NODAT group (p < 0.0001), however, in the multi variant analysis, that difference was not confirmed. Thus, in our group, CMV is of no relevance with the development of NODAT in the monitored period. The survival of patients and graft was 12 months after kidney transplantation without any statistically significant difference between the monitored groups (P = 0.6113 - survival of the patient; P = 0.5381 – survival of the graft). Conclusion: Our analysis shows that in regular monitoring of CMV viremia and applying chemoprophylaxison the risk recipeints, CMV is not the risk factor for NODAT.
{"title":"Correlation between CMV Infection and NODAT","authors":"I. Dedinská, M. StanÄík, L. Laca, J. Miklušica, D. Kantárová, J. Ulinako, J. Janek, P. Galajda, M. MokáÅ","doi":"10.4172/2167-0943.1000205","DOIUrl":"https://doi.org/10.4172/2167-0943.1000205","url":null,"abstract":"Purpose: New-onset diabetes mellitus after transplantation (NODAT) is a well-known complication of transplantation. \u0000Materials and methods: Retrospectively, we detected CMV replication (PCR) in every month after transplantation of kidney in the first 12 months after transplantation in patients in a homogenous group from the aspect of immunosuppresion. \u0000Results: In the group of 167 patients (control group: n = 103, NODAT group: n = 64), the average value of CMV viremia was without any significant difference between the NODAT group and the control group (P = 0.9285). In the 10th month after kidney transplantation, we recorded significantly higher CMV viremia in the NODAT group (p < 0.0001), however, in the multi variant analysis, that difference was not confirmed. Thus, in our group, CMV is of no relevance with the development of NODAT in the monitored period. The survival of patients and graft was 12 months after kidney transplantation without any statistically significant difference between the monitored groups (P = 0.6113 - survival of the patient; P = 0.5381 – survival of the graft). \u0000Conclusion: Our analysis shows that in regular monitoring of CMV viremia and applying chemoprophylaxison the risk recipeints, CMV is not the risk factor for NODAT.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84158497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-16DOI: 10.4172/2167-0943.1000204
S. Raina
It is time we understand the need for disease/s specific programs and not just theoretical frameworks like the National Health Mission (NHM) or National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke, through mixing of programs. Off course, each of these programs can benefit from the strengths of other programs, for example, a program on diabetes can benefit from a fully operational Integrated disease surveillance program (IDSP) or vice versa. A disease specific program is also important because the numbers which diseases like Diabetes or Cardiovascular diseases throw up individually is huge. Importantly these diseases are and will continue to be major contributors of mortality.
{"title":"From NHM to NPCDCS: Epidemiological Transition and Need for a National Program for Diabetes in India","authors":"S. Raina","doi":"10.4172/2167-0943.1000204","DOIUrl":"https://doi.org/10.4172/2167-0943.1000204","url":null,"abstract":"It is time we understand the need for disease/s specific programs and not just theoretical frameworks like the National Health Mission (NHM) or National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke, through mixing of programs. Off course, each of these programs can benefit from the strengths of other programs, for example, a program on diabetes can benefit from a fully operational Integrated disease surveillance program (IDSP) or vice versa. A disease specific program is also important because the numbers which diseases like Diabetes or Cardiovascular diseases throw up individually is huge. Importantly these diseases are and will continue to be major contributors of mortality.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"136 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77472374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-26DOI: 10.4172/2167-0943.1000203
Brian Miller, M. Fridline
Purpose: The purpose of the current investigation was to assess Metabolic Syndrome prevalence and risk estimates using United States nationally representative data. Methods: Study sample was derived from 6 National Health and Nutrition Examination Survey (NHANES) cohorts from 2001-2012, N = 9,326 (male: n = 4,814; female: n = 4,512) including ages 18-59 presenting as fasted for 12 hours prior to laboratories collection. Variables included AHA/NHBLI Metabolic Syndrome classification criteria as well as additional cardiometabolic measures. Prevalence of Metabolic Syndrome and risk factors across cohorts as well as relative risk estimates were derived. Estimates were adjusted for age, race, and sex. Results: There was no statistically significant difference between Metabolic Syndrome prevalence across cohorts. The order of Metabolic Syndrome criteria from highest to lowest risk were waist circumference, triglycerides, HDL, fasting plasma glucose, and blood pressure for the total sample and across sex, with women presenting with larger risk estimates than men. Women had larger prevalence of waist circumference, HDL, and blood pressure risk factors compared to men who had a larger prevalence of triglyceride and fasting plasma glucose risk factors. Those presenting with Metabolic Syndrome were twice as likely to have a cardiovascular event. Conclusion: Waist circumference and triglycerides were the Metabolic Syndrome risk factors with the highest prevalence and associated risk of developing Metabolic Syndrome. Those with Metabolic Syndrome were at increased risk of having a cardiovascular event.
{"title":"Metabolic Syndrome Prevalence and Risk in the United States based on NHANES 2001-2012 Data","authors":"Brian Miller, M. Fridline","doi":"10.4172/2167-0943.1000203","DOIUrl":"https://doi.org/10.4172/2167-0943.1000203","url":null,"abstract":"Purpose: The purpose of the current investigation was to assess Metabolic Syndrome prevalence and risk estimates using United States nationally representative data. \u0000Methods: Study sample was derived from 6 National Health and Nutrition Examination Survey (NHANES) cohorts from 2001-2012, N = 9,326 (male: n = 4,814; female: n = 4,512) including ages 18-59 presenting as fasted for 12 hours prior to laboratories collection. Variables included AHA/NHBLI Metabolic Syndrome classification criteria as well as additional cardiometabolic measures. Prevalence of Metabolic Syndrome and risk factors across cohorts as well as relative risk estimates were derived. Estimates were adjusted for age, race, and sex. \u0000Results: There was no statistically significant difference between Metabolic Syndrome prevalence across cohorts. The order of Metabolic Syndrome criteria from highest to lowest risk were waist circumference, triglycerides, HDL, fasting plasma glucose, and blood pressure for the total sample and across sex, with women presenting with larger risk estimates than men. Women had larger prevalence of waist circumference, HDL, and blood pressure risk factors compared to men who had a larger prevalence of triglyceride and fasting plasma glucose risk factors. Those presenting with Metabolic Syndrome were twice as likely to have a cardiovascular event. \u0000Conclusion: Waist circumference and triglycerides were the Metabolic Syndrome risk factors with the highest prevalence and associated risk of developing Metabolic Syndrome. Those with Metabolic Syndrome were at increased risk of having a cardiovascular event.","PeriodicalId":16452,"journal":{"name":"Journal of metabolic syndrome","volume":"20 1","pages":"0-0"},"PeriodicalIF":0.0,"publicationDate":"2016-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87464962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：